Plus: Parental choice and the midterms; Democrats and Republicans unite on an opioid fix; and a last chance to join FREOPP in D.C. on November 10
Archive
Prostate cancer drug Xtandi’s price increased more than 48 percent from 2013 to 2021.
100% of revenue growth for rheumatoid arthritis drug Enbrel came from price increases, totaling $21 billion over 10 years.
Since 2011, the price of lung cancer drug Alimta has increased by about 25%.
Over a 10-year period, Biogen more than quintupled the price of multiple sclerosis drug Tysabri.
Avastin’s price increased nearly 50 percent from 2011 to 2019, and is still above its 2011 price despite the launch of biosimilars for the cancer drug.
100% of HIV drug Truvada’s revenue growth came from price increases totaling $5.7 billion.
Net prices for arthritis drug Orencia increased more than 113% from 2011 to 2020.